SCHEMBL5539532

SCHEMBL5539532

Cc1nc(-c2ccccc2Cl)oc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 2/20 0.55
IKBKB O14920 1/20 0.50
C1R P00736 1/20 0.49
KDM4E B2RXH2 6/20 0.48
ALDH1A1 P00352 6/20 0.48
HSD17B10 Q99714 2/20 0.48
ELANE P08246 1/20 0.47
MAPT P10636 4/20 0.47
KMT2A Q03164 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
MEN1 O00255 2/20 0.45
MAPK1 P28482 1/20 0.45
NOTUM Q6P988 2/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
CASP3 P42574 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539525 0.82 TP53 (0.52) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL5544481 0.82 NPC1 (0.52) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL1436022 0.80 MEN1 (0.53) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL27361920 0.78 IKBKB (0.51) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL5545407 0.78 NPC1 (0.50) NPC1RAB9ASMN1; SMN2HPGDC1R
SCHEMBL16527705 0.77 IKBKB (0.57) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL11623813 0.76 IKBKB (0.63) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL11626566 0.76 IKBKB (0.72) TP53NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3389561 0.73 DHODH (0.35) RAB9AKDM4EKMT2AMEN1MAPK1
SCHEMBL436384 0.72 GAA (0.57) NPC1RAB9ASMN1; SMN2HPGDIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TP53 4494/4885NPC1 2404/4885RAB9A 2824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.